Fortress Biotech, Inc.

Activist

First SEC filing: Jan. 6, 2026 · Latest: Jan. 6, 2026

On this page

Biography Career background and public profile, where available.
Insider at Companies where this person is a reporting insider.
Insider transactions Every share this person bought or sold, from Form 4 filings.
Derivatives Options and other derivative holdings reported by this person.
Initial holdings The stakes this person held when they first started reporting.

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

History

The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.

In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.

Subsidiaries

Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).

Products

Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.

== References ==

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

Insider at

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 37 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

37 other filings hidden

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
May 30, 2025	FBIOP	D	6,122,249	$4.10	$25,101,221	0 Direct	-100.00%	Disposed	347.6% (price as of 2026-08-21)
May 30, 2025	FBIOP	D	700,000	—	—	0 Direct	-100.00%	Disposed	(price as of 2026-08-21)
May 29, 2025	FBIOP	S	100,000	$1.29	$129,000	6,122,249 Direct	-1.61%	Disposed	1322.5% (price as of 2026-08-21)
March 31, 2025	FBIOP	A	33,724	—	—	328,524 Direct	+11.44%	Acquired	(price as of 2026-08-21)
March 31, 2025	FBIOP	A	67,806	—	—	198,858 Direct	+51.74%	Acquired	(price as of 2026-08-21)
Feb. 26, 2025	FBIOP	A	18,500	—	—	6,222,249 Direct	+0.30%	Acquired	(price as of 2026-08-21)
Jan. 1, 2025	FBIOP	A	2,386,808	—	—	6,203,749 Direct	+62.53%	Acquired	(price as of 2026-08-21)
Dec. 31, 2024	FBIOP	A	81,407	—	—	3,816,941 Direct	+2.18%	Acquired	(price as of 2026-08-21)
Sept. 27, 2024	FBIOP	A	146,341	—	—	3,735,534 Direct	+4.08%	Acquired	(price as of 2026-08-21)
June 27, 2024	FBIOP	A	575,191	—	—	2,502,991 Direct	+29.84%	Acquired	(price as of 2026-08-21)
April 16, 2024	FBIOP	A	413,507	—	—	3,547,393 Direct	+13.19%	Acquired	(price as of 2026-08-21)
March 20, 2024	FBIOP	A	193,905	—	—	2,096,278 Direct	+10.19%	Acquired	(price as of 2026-08-21)
Jan. 2, 2024	FBIOP	A	419,092	—	—	1,927,800 Direct	+27.78%	Acquired	(price as of 2026-08-21)
Jan. 2, 2024	FBIOP	A	2,101,496	—	—	3,133,886 Direct	+203.56%	Acquired	(price as of 2026-08-21)
Dec. 29, 2023	FBIOP	A	158,134	—	—	1,902,373 Direct	+9.07%	Acquired	(price as of 2026-08-21)
Sept. 25, 2023	FBIOP	A	80,906	—	—	1,744,239 Direct	+4.86%	Acquired	(price as of 2026-08-21)
June 30, 2023	FBIOP	A	81,406	—	—	1,663,333 Direct	+5.15%	Acquired	(price as of 2026-08-21)
May 12, 2023	DERM	J	50,000	—	—	3,860,467 Direct	-1.28%	Disposed	(price as of 2026-08-21)
April 4, 2023	FBIOP	A	42,500	—	—	1,581,927 Direct	+2.76%	Acquired	(price as of 2026-08-21)
March 31, 2023	FBIOP	A	52,419	—	—	613,980 Direct	+9.33%	Acquired	(price as of 2026-08-21)
March 31, 2023	FBIOP	A	35,714	—	—	1,539,427 Direct	+2.38%	Acquired	(price as of 2026-08-21)
Feb. 12, 2023	DERM	J	50,000	—	—	3,910,467 Direct	-1.26%	Disposed	(price as of 2026-08-21)
Jan. 6, 2023	FBIOP	A	2,807,008	—	—	22,630,620 Direct	+14.16%	Acquired	(price as of 2026-08-21)
Jan. 5, 2023	FBIOP	A	368,907	—	—	1,503,713 Direct	+32.51%	Acquired	(price as of 2026-08-21)
Jan. 3, 2023	FBIOP	A	231,316	—	—	561,561 Direct	+70.04%	Acquired	(price as of 2026-08-21)
Dec. 31, 2022	FBIOP	A	90,909	—	—	330,245 Direct	+37.98%	Acquired	(price as of 2026-08-21)
Nov. 12, 2022	DERM	J	50,000	—	—	3,960,467 Direct	-1.25%	Disposed	(price as of 2026-08-21)
Aug. 12, 2022	DERM	J	50,000	—	—	4,010,467 Direct	-1.23%	Disposed	(price as of 2026-08-21)
May 12, 2022	DERM	J	50,000	—	—	4,060,467 Direct	-1.22%	Disposed	(price as of 2026-08-21)
March 31, 2017	FBIOP	A	1,600	—	—	10,132,653 Direct	+0.02%	Acquired	(price as of 2026-08-21)
March 17, 2017	FBIOP	A	721,699	—	—	2,702,705 Direct	+36.43%	Acquired	(price as of 2026-08-21)
March 13, 2017	FBIOP	A	767,264	—	—	10,131,053 Direct	+8.19%	Acquired	(price as of 2026-08-21)
Jan. 31, 2017	FBIOP	A	213,419	—	—	9,363,789 Direct	+2.33%	Acquired	(price as of 2026-08-21)
Dec. 29, 2016	FBIOP	A	15,806	—	—	9,150,370 Direct	+0.17%	Acquired	(price as of 2026-08-21)
Dec. 12, 2016	FBIOP	A	11,925	—	—	9,134,564 Direct	+0.13%	Acquired	(price as of 2026-08-21)
Nov. 30, 2016	FBIOP	A	47,505	—	—	9,122,639 Direct	+0.52%	Acquired	(price as of 2026-08-21)
Oct. 25, 2016	FBIOP	A	27,264	—	—	9,075,134 Direct	+0.30%	Acquired	(price as of 2026-08-21)
Sept. 30, 2016	FBIOP	A	47,870	—	—	9,047,870 Direct	+0.53%	Acquired	(price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
May 30, 2025	FBIOP	CLASS A COMMON STOCK, PAR VALUE $0.0001	Common Stock (700,000)	$4.10	—	700,000	Disposed

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 12 holdings

Securities held when first becoming an insider, per SEC Form 3.

Date	Ticker	Security	Shares	Ownership
Jan. 3, 2025	FBIOP	COMMON STOCK, PAR VALUE $0.0001	6,552,784	Direct
Jan. 3, 2025	FBIOP	COMMON STOCK, PAR VALUE $0.0001	294,800	Direct
May 31, 2024	DERM	COMMON STOCK, PAR VALUE $0.0001	4,110,467	Direct
May 31, 2024	DERM	Common stock - Class A, $0.0001 par value→ Common Stock (6,000,000)	6,000,000	Direct
May 24, 2024	FBIOP	COMMON STOCK, PAR VALUE $0.0001	3,589,193	Direct
May 24, 2024	FBIOP	CLASS A COMMON STOCK, PAR VALUE $0.0001→ Common Stock (700,000)	700,000	Direct
Aug. 23, 2017	FBIOP	Common Stock	3,316,259	Direct
Aug. 23, 2017	FBIOP	Class A Preferred Stock	250,000	Direct
June 7, 2017	FBIOP	Common Stock, $0.0001 par value	1,981,006	Direct
June 7, 2017	FBIOP	Class A Common Stock, $0.001 par value→ Common Stock (7,000,000)	7,000,000	Direct
June 7, 2017	FBIOP	Common Stock, par value $0.0001	9,000,000	Direct
June 7, 2017	FBIOP	Class A Preferred Stock, $0.0001 par value→ Common Stock (250,000)	250,000	Direct